UNSPSC 51363001: Clomethiazole

This classification denotes a sedative and hypnotic with the molecular formula C6H8ClNS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C5DBZ19HV, chemically known as thiazole, 5-(2-chloroethyl)-4-methyl- but generally known as clomethiazole, which bears US NIH Compound Identifier 10783. European Medicines Agency schedules Clomethiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06720MIG. The term CLOMETHIAZOLE is an International Non-Proprietary Name.

UNSPSC 51363001 Clomethiazole (Commodity) covers pharmaceutical products that state and local governments procure through both direct supply and cooperative purchasing arrangements, though recent opportunities under this code show minimal direct activity for clomethiazole itself and instead reflect broader pharmaceutical procurement patterns—naloxone and drug deactivation systems, generic multi-source pharmaceuticals through state purchasing cooperatives, and exploratory direct-to-manufacturer prescription programs. The issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances serving state and local facilities (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Procurement spans community health initiatives focused on opioid response, state pharmacy benefit programs seeking cost management and supply-chain efficiency, and cooperative arrangements covering multiple jurisdictions and state employee health plans.

Recent activity clusters in Florida and the upper Midwest, with additional multistate coordination through MMCAP involving Oregon and other participating members. Representative opportunities include Seminole County's IFB60459723LAS (IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, response due July 26, 2023), the Texas HHS Commission's RFI HHS0017013 (exploratory request for information on direct-to-manufacturer prescription capabilities, posted April 3, 2026), and MMCAP's S1070000015802 (RFP for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, targeting July 1, 2026 contract effectiveness). These opportunities emphasize wholesale distribution relationships, cGMP and DSCSA compliance, NDC-level product specifications, and multi-year contract terms with optional renewals. No recent opportunities name clomethiazole specifically; the code shows general pharmaceutical procurement activity rather than demand concentrated on this single drug product.